Drugs pricing accord behind revenue fall: Roche

The main Irish arm of Swiss drugs giant Roche has blamed a new pricing agreement with the Government for “a significant decline in revenues” in 2017.

That is according to new accounts filed by Roche Products (Ireland) Ltd which show that pre-tax profits fell 7% to €5m, as revenues declined 6% €101.7m.